NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free FULC Stock Alerts $7.38 -0.07 (-0.94%) (As of 09:34 AM ET) Add Compare Share Share Today's Range$7.34▼$7.4250-Day Range$6.84▼$8.6552-Week Range$2.95▼$13.70Volume5,373 shsAverage Volume601,258 shsMarket Capitalization$458.67 millionP/E RatioN/ADividend YieldN/APrice Target$15.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fulcrum Therapeutics alerts: Email Address Fulcrum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.0% Upside$15.57 Price TargetShort InterestBearish5.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 5 Articles This WeekInsider TradingSelling Shares$1,831 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.24) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector722nd out of 913 stocksPharmaceutical Preparations Industry338th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFulcrum Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Fulcrum Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.78% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Fulcrum Therapeutics has recently increased by 16.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FULC. Previous Next 2.9 News and Social Media Coverage News SentimentFulcrum Therapeutics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for FULC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,831.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($1.24) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fulcrum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIThe best trading strategy for markets right nowAre we in a bull market or about to head into a recession? Will there be war or will there be peace? Will interest rates rise or go lower? Who knows! And I don’t really care. Because I’ve discovered a trading strategy that doesn’t depend on what the rest of the world is doing. But with just one trade, I can target up to $2k or more in trade income every single week, starting with as little as $500. To see how I do it click here. About Fulcrum Therapeutics Stock (NASDAQ:FULC)Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FULC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FULC Stock News HeadlinesMay 21, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight RecommendationMay 16, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug ProspectsMay 14, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)May 14, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?May 14, 2024 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | finance.yahoo.comFulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...May 13, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | globenewswire.comFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular DystrophyMay 12, 2024 | markets.businessinsider.comHere's what to expect from Fulcrum Therapeutics's earningsMay 9, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate in Upcoming May ConferencesMay 8, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet NeurologyMay 6, 2024 | globenewswire.comFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ETMay 1, 2024 | finance.yahoo.comEpsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company ExpansionApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialMarch 28, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumMarch 22, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | finance.yahoo.comFULC Apr 2024 9.000 putMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)March 18, 2024 | finanznachrichten.deFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 18, 2024 | msn.comFulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical OfficerMarch 18, 2024 | globenewswire.comFulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 13, 2024 | tmcnet.comFulcrum Deepens Collaboration with Esri, Recognized as Bronze PartnerMarch 8, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FULC CUSIPN/A CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Stock Price Target$15.57 High Stock Price Target$23.00 Low Stock Price Target$11.00 Potential Upside/Downside+109.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,330,000.00 Net Margins-3,470.05% Pretax Margin-3,961.20% Return on Equity-40.60% Return on Assets-37.19% Debt Debt-to-Equity RatioN/A Current Ratio20.38 Quick Ratio20.38 Sales & Book Value Annual Sales$2.81 million Price / Sales164.77 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book1.96Miscellaneous Outstanding Shares62,150,000Free Float59,606,000Market Cap$463.02 million OptionableOptionable Beta2.34 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Alexander C. Sapir (Age 57)CEO, President & Director Comp: $961.26kMr. Alan A. Musso C.M.A. (Age 62)CPA, Chief Financial Officer Comp: $545.1kMr. Curtis G. Oltmans J.D. (Age 61)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $585.4kMr. Mel Hayes (Age 54)Executive Vice President of Patient Experience Comp: $631.5kDr. Bradley E. Bernstein M.D.Ph.D., FounderDr. Michael R. GreenFounderDr. Rudolf Jaenisch M.D.Ph.D., FounderDr. Tsun-Huei Lee M.D. (Age 60)Ph.D., Founder Dr. Danny ReinbergFounderMr. Gregory TourangeauController & Principal Accounting OfficerMore ExecutivesKey CompetitorsOrchard TherapeuticsNASDAQ:ORTXbluebird bioNASDAQ:BLUESangamo TherapeuticsNASDAQ:SGMOKezar Life SciencesNASDAQ:KZRKeros TherapeuticsNASDAQ:KROSView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 188,212 shares on 5/16/2024Ownership: 0.861%Jacobs Levy Equity Management Inc.Sold 101,658 shares on 5/16/2024Ownership: 0.033%StemPoint Capital LPBought 30,535 shares on 5/14/2024Ownership: 0.655%Vanguard Group Inc.Bought 18,681 shares on 5/10/2024Ownership: 4.084%SG Americas Securities LLCBought 12,206 shares on 5/7/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions FULC Stock Analysis - Frequently Asked Questions Should I buy or sell Fulcrum Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FULC shares. View FULC analyst ratings or view top-rated stocks. What is Fulcrum Therapeutics' stock price target for 2024? 7 brokerages have issued 12-month price targets for Fulcrum Therapeutics' shares. Their FULC share price targets range from $11.00 to $23.00. On average, they predict the company's share price to reach $15.57 in the next year. This suggests a possible upside of 109.0% from the stock's current price. View analysts price targets for FULC or view top-rated stocks among Wall Street analysts. How have FULC shares performed in 2024? Fulcrum Therapeutics' stock was trading at $6.75 at the beginning of 2024. Since then, FULC stock has increased by 10.4% and is now trading at $7.45. View the best growth stocks for 2024 here. Are investors shorting Fulcrum Therapeutics? Fulcrum Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 3,590,000 shares, an increase of 16.2% from the May 15th total of 3,090,000 shares. Based on an average daily volume of 539,700 shares, the days-to-cover ratio is currently 6.7 days. View Fulcrum Therapeutics' Short Interest. When is Fulcrum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our FULC earnings forecast. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 40.60% and a negative net margin of 3,470.05%. What ETFs hold Fulcrum Therapeutics' stock? ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Simplify Health Care ETF (PINK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO). When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.08%), Jane Street Group LLC (0.86%), StemPoint Capital LP (0.66%), Mass General Brigham Inc (0.33%), Commonwealth Equity Services LLC (0.13%) and Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FULC) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
